GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hangzhou Alltest Biotech Co Ltd (SHSE:688606) » Definitions » EBIT

Hangzhou Alltest Biotech Co (SHSE:688606) EBIT : ¥306.5 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Hangzhou Alltest Biotech Co EBIT?

Hangzhou Alltest Biotech Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥84.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥306.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hangzhou Alltest Biotech Co's annualized ROC % for the quarter that ended in Sep. 2024 was 22.22%. Hangzhou Alltest Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 35.08%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hangzhou Alltest Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 9.26%.


Hangzhou Alltest Biotech Co EBIT Historical Data

The historical data trend for Hangzhou Alltest Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Alltest Biotech Co EBIT Chart

Hangzhou Alltest Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 84.21 813.32 896.20 1,383.62 198.90

Hangzhou Alltest Biotech Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.08 82.77 47.29 92.12 84.27

Competitive Comparison of Hangzhou Alltest Biotech Co's EBIT

For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Alltest Biotech Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hangzhou Alltest Biotech Co's EV-to-EBIT falls into.


;
;

Hangzhou Alltest Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥306.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Alltest Biotech Co  (SHSE:688606) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hangzhou Alltest Biotech Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=316.724 * ( 1 - 12.07% )/( (1213.912 + 1292.635)/ 2 )
=278.4954132/1253.2735
=22.22 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4179.337 - 283.358 - ( 2682.067 - max(0, 362.226 - 3052.054+2682.067))
=1213.912

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4164.664 - 208.934 - ( 2663.095 - max(0, 274.295 - 3022.645+2663.095))
=1292.635

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hangzhou Alltest Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=337.096/( ( (908.075 + max(4.542, 0)) + (926.147 + max(83.178, 0)) )/ 2 )
=337.096/( ( 912.617 + 1009.325 )/ 2 )
=337.096/960.971
=35.08 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(111.18 + 160.288 + 90.808) - (283.358 + 0 + 74.376)
=4.542

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(109.797 + 152.694 + 91.041) - (208.934 + 0 + 61.42)
=83.178

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hangzhou Alltest Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=306.45/3307.667
=9.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Alltest Biotech Co EBIT Related Terms

Thank you for viewing the detailed overview of Hangzhou Alltest Biotech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Alltest Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 550, Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Building 3-5, Zhejiang Province, Hangzhou, CHN, 310018
Hangzhou Alltest Biotech Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents.
Executives
Fu Yan Ping senior management
Lu Wei Ke Directors, senior managers, core technical personn
Gao Fei Directors, senior managers, core technical personn

Hangzhou Alltest Biotech Co Headlines

No Headlines